BioCentury
ARTICLE | Clinical News

ALN-CC5: Additional Phase I/II data

December 14, 2015 8:00 AM UTC

Data from 32 healthy volunteers in the double-blind first and second parts of a 3-part, U.K. Phase I/II trial showed that single and multiple subcutaneous doses of ALN-CC5 reduced mean maximum serum C...